anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: Alterations in metabolic status, body composition, and food intake are present in all neurodegenerative diseases. Aim of this study was to detect the progression of these changes in Progressive Supranuclear Palsy (PSP).
METHODS: We conducted a longitudinal study of 15 patients with PSP. The assessments were performed at baseline (T0) and after 7(IQR = 5) months of follow-up (T1). We collected anthropometric measures including body weight, height, body mass index and waist circumference, metabolic parameters through indirect calorimeters, body composition using bioimpedance analysis, and dietary habits with a validated questionnaire. PSP-rating scale (PSP-rs) was used to evaluate disease severity and dysphagia.
RESULTS: The majority of patients (66.66%) presented PSP-Richardson Syndrome and 33.33% the other variant syndromes of the disease. At T1 there was a decrease in intake of total daily calories (p < 0.001), proteins (p < 0.001), fibers (p = 0.001), calcium (p = 0.008), iron (p < 0.001), zinc (0.034), vitamin E (p = 0.006) and folates (p = 0.038) compared to T0. No other changes were found. As for T1 data, no significant differences were shown according to disease phenotypes or the presence of clinically significant dysphagia for solids.
CONCLUSIONS: Within a mid-term follow up, PSP patients presented reduced caloric and proteins intake regardless the presence of dysphagia. The PSP-rs is likely not adequate to assess dysphagia, which should be investigated by specific clinical scales or instrumental examinations. With the goal of maintaining adequate nutritional status, the administration of protein and vitamin supplements should be considered even in the absence of dysphagia evidenced by the rating scales.
The invention discloses a preparation method of atomized liquid for preoperative intervention and aims to solve the problem of broncholithiasis treatment. The preparation method comprises the following steps: extracting volatile oil for standby use from leaves of Cunninghamia lanceolata (Lamb.) Hook., leaves of cannabis sativa L., Rabdosia sculponeata (Vaniot) Hara and Bulbophyllum inconspicuum Maxim. by steam distillation, and reserving residues; mixing adult Gryllotalpa africana Palisot et Beaurois (or adult G. unispina Saussure), root of small-leaf oriental grape, root of Rubus wilsonii Duthie, seeds of Carex baccans Nees, larval Holotrichia diomphalia Bates (or larval Anomala carpulenta Motsch.), Buchnera cruciatas Hamilt., root of Salix wallichiana Anders., seeds of Euryale ferox Salisb. and the residues obtained in step 1, and performing aqueous extraction to obtain an extract; concentrating the extract under reduced pressure, adding ethyl alcohol into the concentrated extract, keeping the concentrated extract standing under refrigeration, taking and filtering supernatant, recycling ethyl alcohol from filtrate, adding 0.5w% of powdered activated carbon into concentrated filtrate, boiling the concentrated filtrate for 30 minutes after uniform stirring, cooling the concentrated filtrate to 50DEG C, and performing suction filtration with a 0.4mu m filter membrane; and adding 0.2w% of potassium sorbate into suction filtrate, mixing the potassium sorbate and the suction filtrate uniformly, and spraying the volatile oil obtained in step 1 into the mixture of the potassium sorbate and the suction filtrate, uniformly mixing the volatile oil and the mixture, and performing subpackaging. Clinical experiments prove that the atomized liquid has the characteristics of good curative effect and high safety in broncholithiasis treatment and is worth application and popularization.
Dose: 1.5 mg A4250 b.i.d. for 7 days.
In Periods 1 and 2, participants will receive oral \[12C\] RO7049389 under fasted conditions, followed by IV \[13C\] RO7049389. There is a minimum 7-day washout between periods.
The present invention belongs to the technical field of alcoholic beverages, which provides a wine for supplementing yuanqi. The present invention is mainly characterized in that natural plant fruits of Chinese date, mulberry, barbary wolfberry fruit, asiatic cornelian cherry fruit, finger citron, etc. are used as principal raw materials, cassia bark, polygonatum, Siberian solomonseal rhizome, tuckahoe, angelica, colla plastri testudinis, spina date seed, radish seed, rock candy, etc. which have nutrient and medicinal efficacy are used as auxiliary materials, and the principal raw materials and the auxiliary materials are soaked in wines to extract essence. The present invention also provides a method for preparing the wine for supplementing yuanqi. When the method is used, effective ingredients in the medicines can be sufficiently extracted, waste can be reduced, the quality of extracting wines can be guaranteed, the production period of preparing the medicated wine is greatly shortened, and the production efficiency is enhanced. Compared with other medicated wines, the wine for supplementing yuanqi of the present invention has good mouth feeling and is sweet and brisk, double efficacy of nutrition nourishment and medicinal health care can be realized, and the wine of the present invention has the functions of resisting fatigue, resisting early ageing, benefiting qi, invigorating the kidney, relieving fatigue, strengthening organic immunological competence, delay aging, etc.
The complex pathogenesis of kidney disease is closely related to the diversity of kidney intrinsic cells. In this study, single-cell transcriptome sequencing technology was used to sequence and analyze blood and kidney tissue cells in normal control rats and rats with chronic kidney disease (CKD), focusing on key cell populations and functional enrichment to explore the pathogenesis of CKD. Oil red O staining and enzyme-linked immunosorbent assay (ELISA) were used to detect lipid droplets and free fatty acid (FFA). Quantitative real-time polymerase chain reaction (RT-PCR), western blot (WB) were used to verify the differential gene hydroxyacid oxidase 2 (HAO2) and fatty acid metabolic process in tissue to ensure the reliability of single-cell sequencing results. We successfully established a single-cell transcriptome atlas of blood and kidney tissue in rats with CKD, which were annotated into 14 cell subsets (MPCs, PT, Tc, DCT, B-IC, A-IC, CNT, ALOH, BC, Neu, Endo, Pla, NKT, Baso) according to marker gene, and the integrated single-cell atlas of rats showed a significant increase and decrease of MPCs and PTs in the CKD group, respectively. Functional analysis found extensive enrichment of metabolic-related pathways in PT cells, includes fatty acid metabolic process, cellular amino acid metabolic process and generation of precursor metabolites and energy. Immunohistochemical experiments determined that the differential gene HAO2 was localized in the renal tubules, and its expression was significantly reduced in CKD group compared with control, and oil red O staining showed that lipid droplets increased in the CKD group, after overexpression of HAO2 the lipid droplets was inhibited. ELISA assay showed that ATP content decreased in the CKD group and FFA increased in the CKD group. Moreover, the mitochondrial membrane potential of the cells in the OE-HAO2 group was significantly increased compared with OE-NC. The acyl-CoA oxidase 1(ACOX1), peroxisome proliferator-activated receptor alpha (PPARα), peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1α) were decreased in the CKD group, while genes and proteins were increased after overexpression of HAO2, and the AMP-activated protein kinase (AMPK) phosphorylated proteins were increased, the acetyl-CoA carboxylase (ACC) phosphorylated proteins were decreased, reversely. Therefore, HAO2 may be an important regulator of fatty acid metabolic processes in CKD, and overexpression of HAO2 can enhance fatty acid metabolism by promoting fatty acid oxidation (FAO) pathway.
PURPOSE:To obtain the title preventive and remedy having no problems of occurrence of resistant bacteria and side effects and no fear of influence of remaining agent on human body, comprising a crude drug such as rhizome of Rheum palmatum Linne, rhizome of Coptis japonica Makino or bark of Phellodendron amurense Ruprecht as an active ingredient. CONSTITUTION:The title preventive and remedy comprising a crude drug selected from the group consisting of rhizome of Rheum palmatum Linne, rhizome of Coptis japonica Makino, bark of Phellodendron amurense Ruprecht, root of Scutellarla bacialensis Georgi, stems and leaves of Geranlum nepalense Sweet, root and rhizome of Glycyrrhiza glabra Linne var. glanduliffera Regel et Herder, stems and leaves of Isodon japonica Hara, dried root of Sanguisorba officinalis L., fruit ear of Humulus Lupulus Linne, gall of Bostaurus domesticus Gmelin, fruit of Cornus officinalis Siebold et Zuccarini, Galla rhois, root of Salvia miltiorrhiza Bunge, rhizome of Picrorrhiza Kurooa Royle ex Benth, Aloe arborescens Mill. var. natalensis Bergel., bud of Eugenia caryophyllata Thumb. and unripe fruit of Prunus Mume Siebold et Zuccarini as an active ingredient. The crude drug is administered in the form of raw powder, essence extracted with an organic solvent or water or an active ingredient of Galla rhois obtained from the essence and a dose thereof is 0.001mg-100g calculated as weight of raw powder per kg weight daily.
Subjects with advanced or metastatic solid tumors will receive THOR-707 Q3W at recommended Phase 2 dose (RP2D) with a checkpoint inhibitor via IV administration Q6W will consist of one 9-week cycle of THOR monotherapy on Cycle 1 Day 1 followed by THOR-707 Q3W + checkpoint inhibitor at Cycle 1 Day 22. Subsequently treatment will consist of repeated 6-weeks cycles with combination therapy.
Agents for promoting bone deposition and growth in a mammalian subject. The agents are O-glycosylated and non-glycosylated peptides that are derived from vitamin D binding protein, collectively referred to hereinafter as "DBP" peptides. The DBP peptides are from 3 to 18, preferably from 4 to 14 amino acids in length and comprise a sequence which is at least 80 % identical, preferably at least 90 % identical to the amino acid sequence of a fragment contained within domain III of DBP. Methods for promoting bone deposition in a subject in need of the same are also provided. The methods comprise administering to the subject a therapeutically effective quantity of an agent selected from the group consisting of an activated form of vitamin D binding protein referred to hereinafter as "ADBP", one or more DBP peptides, and combinations thereof. The agents may be administered locally or systemically.
Hypoxic-ischemic encephalopathy (HIE) is one of the most common causes of childhood disability. Hypothermic therapy is currently the only approved neuroprotective approach. However, early diagnosis of HIE can be challenging, especially in the first hours after birth when the decision to use hypothermic therapy is critical. Distinguishing HIE from other neonatal conditions, such as sepsis, becomes a significant problem in diagnosis. This study explored the utility of a metabolomic-based approach employing the NeoBase 2 MSMS kit to diagnose HIE using dry blood stains in a Rice-Vannucci model of HIE in rats. We evaluated the diagnostic fidelity of this approach in a range between 3 and 6 h after the onset of HIE, including in the context of systemic inflammation and concomitant hypothermic therapy. Discriminant analysis revealed several metabolite patterns associated with HIE. A logistic regression model using glycine levels achieved high diagnostic fidelity with areas under the receiver operating characteristic curve of 0.94 at 3 h and 0.96 at 6 h after the onset of HIE. In addition, orthogonal partial least squares discriminant analysis, which included five metabolites, achieved 100% sensitivity and 80% specificity within 3 h of HIE. These results highlight the significant potential of the NeoBase 2 MSMS kit for the early diagnosis of HIE and could improve patient management and outcomes in this serious illness.
BACKGROUND: Postoperative sleep disturbance has a potentially detrimental effect on postoperative recovery. Perioperative patients are affected by several factors. General anesthesia induces a non-physiological state that does not resemble natural sleep. Exposure to propofol/sevoflurane can lead to desynchronization of the circadian rhythm, which may result in postoperative sleep disturbance characterized by mid-cycle advancement of sleep and daytime sleepiness. Dexmedetomidine is a highly selective α2-adrenoceptor agonist with a unique sedative effect that facilitates the transition from sleep to wakefulness. Basic research has shown that dexmedetomidine induces deep sedation, similar to physical sleep, and helps maintain forebrain connectivity, which is likely to reduce delirium after surgery. The aim of this study is to evaluate the influence of exposure to the mono-anesthetic propofol on the development of postoperative sleep disturbance in young and middle-aged female patients undergoing hysteroscopy and whether prophylactic administration of dexmedetomidine influences reducing postoperative sleep disturbance.
METHODS: This prospective randomized controlled trial (RCT) will include 150 patients undergoing hysteroscopy at the First Affiliated Hospital of Xiamen University. Participants will be randomly assigned to three groups in a 1:1:1 ratio. The dexmedetomidine group will have two subgroups and will receive a nasal spray of 0.2 µg/kg or 0.5 µg/kg 25 min before surgery, while the control group will receive a saline nasal spray. Three groups will undergo hysteroscopy with propofol-based TIVA according to the same scheme. Sleep quality will be measured using a wearable device and double-blind sleep assessments will be performed before surgery and 1, 3, and 7 days after surgery. SPSS 2.0 is used for statistical analysis. A χ2 test is used to compare groups, and t-test is used to determine statistical the significance of continuous variables.
DISCUSSION: The purpose of this study is to investigate the incidence of propofol-associated sleep disorders and to test a combination of dexmedetomidine anesthesia regimen for the prevention of postoperative sleep disorders. This study will help to improve patients' postoperative satisfaction and provide a new strategy for comfortable perioperative medical treatment.
TRIAL REGISTRATION: ClinicalTrials.gov NCT06281561. Registered on February 24, 2024.
Aqueous skin cleaning agents in the form of viscous lotions, creams or gels containing vegetal abrasive materials, e.g. natural flours made from ground kernels, pods or seeds, have high stability with regard to enzymatic decomposition of thickening agents when the thickening agents used are biopolymers from the group of extracellular microbial polysaccharides, preferably xanthan gum. Preferred skin cleaning preparations contain 0.5-30 wt. % vegetal abrasives, optionally 0-20 wt. % other abrasive substances, 0.1-5 wt. % microbial polysaccharide thickening agents, 0.1-20 wt. % surfactants, 1-20 wt. % glycol, polyol or polyethylene glycol and 20-40 wt. % water.
The present invention is a cosmetic or dermatological topical formulation based on an oil-in-water emulsion, comprising (a) 0.05 wt. % to 2 wt. %, based on the total weight of the formulation, of one or more ethoxylated fatty acid esters selected from the group consisting of PEG-5 to PEG-100 stearates; (b) 0.5 wt. % to 20 wt. %, based on the total weight of the formulation, of glycerin; and (c) one or more of (i) 0.1 wt. % to 6 wt. %, based on the total weight of the formulation, of glycerol monostearate, and (ii) 0.1 wt. % to 8 wt. %, based on the total weight of the formulation, of one or more C 16 -C 18  fatty alcohols. The present invention also includes a method of using the formulation to moisturize the skin and a method of using the formulation to limit aging of the skin, limit the formation of wrinkles, treat aged skin and/or treat wrinkles.
Water is produced containing extracted ingredients from plant, animal and/or mineral matter. Raw material is placed into contact with an absorber material, which holds the raw material after drying. Atomized heated water is applied to the absorber material in a depressurized state to extract effective ingredients from the raw material. The atomized particles containing the extracted ingredients are circulated with air and delivered to a cooled condenser. Water containing the effective ingredients is collected in a reservoir tank after being condensed by the condenser. Atomized fine particles that are not condensed are recirculated.
Compositions and methods for treating a subject for a SARS-CoV-2 infection in a subject in need thereof are disclosed. The composition includes one or more Bismuth (III)-containing compounds, an analog thereof, or pharmaceutically acceptable salt thereof in a pharmaceutically acceptable carrier, and are used alone or in combination with a thiol-containing small molecule compound. Exemplary Bismuth (III)-containing compounds include Colloidal Bismuth Subcitrate (CBS); ranitidine bismuth citrate (RBC); Bi (TPP) (TPP: tetraphenylporphyrinate); and Bi (TPyP) (TPyP: tetra (4-pyridyl) porphyrin). The disclosed compounds and compositions can be used to treat a SARS-CoV-2 infection in a subject in need thereof. The compositions can be administered to a subject presently suffering from an infection of the SARS-CoV-2, who is exhibiting one or more symptoms of COVID-19. The compositions can also be administered to a subject that has been exposed to the SARS-CoV-2 but is asymptomatic.
In this Phase II, open-label study, the treatment period will consist of an induction phase and a maintenance phase. The induction phase consists of an induction treatment cycle of 8 weeks which is the DLT period. The maintenance phase consists of treatment cycles of 56 days (8 weeks) each, and may extend up to 2 years. During the induction phase, ipilimumab will be administered on day 1 at a dose of 1 mg/kg intravenously (IV) during the 8-week induction period, concurrent with nivolumab 480 mg/relatlimab at 160 mg, fixed dose, administered at a 4 week interval on days 1 and 29 with a 30 minute rest period between the two infusions on day 1 and 29. On days administered in combination, nivolumab/relatlimab will be administered first at a dose of 480 mg/160 mg, followed by ipilimumab at 1 mg/kg, and immediately followed by sarilumab at 150 mg given subcutaneously. Nivolumab/relatlimab and ipilimumab will be each administered IV over 30 minutes consecutively with a 30-minute rest period between infusions, on day 1 of the first and all subsequent 56-day maintenance treatment cycles and nivolumab/relatlimab will be administered on day 29 of each cycle. Sarilumab will be administered subcutaneously every 2 weeks during the 56-day induction treatment cycle and the first two 56-day maintenance cycles only for a total of 24 weeks
Disclosed in the present invention are a group of humanized broad-spectrum anti-SARS-CoV-2 monoclonal neutralizing antibodies. The neutralizing antibodies of the present invention are screened by a single B cell flow sorting-antibody gene amplification and pairing expression technology, have a unique CDR region, can specifically bind to SARS-CoV-2, and can effectively neutralize current multiple international epidemic virus strains (new crown mutant A, British mutant B1.1.7, South Africa mutant B.1.351, Brazil mutant P.1, and Indian mutants B.1.617.1 and B1.617.2), wherein the IC 50 is about 0.1 μg/ml. The present invention also relates to a preparation method for and a use of the group of neutralizing antibodies. Every two of the three antibodies of the present invention have a synergistic virus neutralizing effect when used in combination. Therefore, the combination of the three antibodies can be used for COVID-19 emergency prevention and/or treatment, has the characteristics of full humanization, high expression and good stability, and is suitable for industrialization. In addition, the antibodies can also be used for preparing SARS-CoV-2 detection reagents, so as to discover effective neutralizing antigen epitopes and develop SARS-CoV-2 recombinant proteins and subunit vaccines.
FIELD: cosmetic industry, particularly, agents for head skin care. SUBSTANCE: balsam contains acidic component, glycerine, oil component, aqueous-alcoholic extracts of plants, and water. Stearic acid is used as an acidic component, while nettle oil extract and ether lavender oil, as an oil component. Aqueous-alcoholic extracts of licorice, sweetflag, birch leaves or buds are used as aqueous-alcoholic extracts of plants. The balsam additionally comprises triethanolamine, emulsion wax, agidol-I, nipagin, nipazol, slimy mud. All ingredients are taken in preset ratio. EFFECT: antiinflammatory and tonic action. 2 cl, 1 tbl
Hypertension:   


Trandolapril tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive medication such as hydrochlorothiazide.

In considering the use of trandolapril tablets, it should be noted that in controlled trials ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients. (See Warnings: Angioedema .)

When using trandolapril tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that trandolapril tablets do not have a similar risk. (See WARNINGS.)